Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S has a collaboration agreement with Embark Biotech ApS for the discovery of novel treatments for obesity and its associated metabolic pathologies. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:NVO
Previous Symbol
CUSIPN/A
Phone45-4444-8888
Debt
Debt-to-Equity RatioN/A
Current Ratio1.10
Quick Ratio0.77
Price-To-Earnings
Trailing P/E Ratio19.87
Forward P/E Ratio18.83
P/E Growth2.19
Sales & Book Value
Annual Sales$16.96 billion
Price / Sales6.70
Cash Flow$2.5676 per share
Price / Cash Flow18.11
Book Value$3.10 per share
Price / Book15.00
Profitability
EPS (Most Recent Fiscal Year)$2.34
Net Income$5.79 billion
Net Margins34.94%
Return on Equity81.50%
Return on Assets38.73%
Miscellaneous
Employees42,076
Outstanding Shares2,443,530,000
Market Cap$113.62 billion
OptionableOptionable
Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S announced a special dividend on Thursday, August 9th. Stockholders of record on Monday, August 20th will be paid a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S announced that its board has approved a share repurchase program on Friday, February 2nd 2018, which authorizes the company to repurchase outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its stock is undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Thursday, November, 1st. The company reported $0.58 EPS for the quarter, hitting analysts' consensus estimates of $0.58. The business had revenue of $4.31 billion for the quarter, compared to analysts' expectations of $4.11 billion. Novo Nordisk A/S had a net margin of 34.94% and a return on equity of 81.50%. View Novo Nordisk A/S's Earnings History.
When is Novo Nordisk A/S's next earnings date?
What guidance has Novo Nordisk A/S issued on next quarter's earnings?
Novo Nordisk A/S issued an update on its FY 2018 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.425-17.592 billion, compared to the consensus revenue estimate of $17.33 billion.
What is the consensus analysts' recommendation for Novo Nordisk A/S?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.
Has Novo Nordisk A/S been receiving favorable news coverage?
Headlines about NVO stock have been trending somewhat positive on Monday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN).
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
- Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
- Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
- Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
- Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)
Who are Novo Nordisk A/S's major shareholders?
Novo Nordisk A/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Loomis Sayles & Co. L P (0.89%), Renaissance Technologies LLC (0.80%), Fisher Asset Management LLC (0.56%), BlackRock Inc. (0.37%), Sustainable Growth Advisers LP (0.16%) and Everett Harris & Co. CA (0.13%). View Institutional Ownership Trends for Novo Nordisk A/S.
Which major investors are selling Novo Nordisk A/S stock?
NVO stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Jane Street Group LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Skba Capital Management LLC, Jefferies Group LLC, United Services Automobile Association and Russell Investments Group Ltd.. View Insider Buying and Selling for Novo Nordisk A/S.
Which major investors are buying Novo Nordisk A/S stock?
NVO stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Renaissance Technologies LLC, Loomis Sayles & Co. L P, Capital International Investors, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Fisher Asset Management LLC and PNC Financial Services Group Inc.. View Insider Buying and Selling for Novo Nordisk A/S.
How do I buy shares of Novo Nordisk A/S?
Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
One share of NVO stock can currently be purchased for approximately $46.50.
How big of a company is Novo Nordisk A/S?
Novo Nordisk A/S has a market capitalization of $113.62 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe.
What is Novo Nordisk A/S's official website?
How can I contact Novo Nordisk A/S?
Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
